Benzene and Acute Myeloid Leukemia: Evidence of Causation and Risk

From General Health Awareness to Occupational Hazard Focus

The legacy of general health and science information has long emphasized the importance of understanding environmental factors in disease prevention. Within this broad context, public health messaging has historically focused on lifestyle choices, infectious disease control, and broad chemical safety awareness. This foundational knowledge established the principle that certain substances, when encountered in daily life, warrant careful scrutiny. As scientific inquiry deepened, attention naturally shifted from generalized health advice to more specific occupational settings where exposure levels can be significantly higher and more sustained. The transition from general health guidance to occupational health concern is particularly evident when examining industrial chemicals that have been subject to decades of research. Among these, benzene stands out as a compound whose health implications have moved from general toxicological interest to a focused occupational exposure concern. In mass production environments, benzene has been widely used as a solvent and chemical intermediate, leading to routine contact for workers in manufacturing, petroleum refining, and chemical processing. This occupational context raises distinct questions about exposure thresholds, duration, and cumulative risk that differ markedly from general population exposure scenarios. The pivot from broad health information to specific workplace hazard assessment represents a natural evolution in public health understanding, where general awareness gives way to targeted occupational risk evaluation.

Benzene as a Recognized Carcinogen: Bridging to Acute Myeloid Leukemia

Building on the understanding that benzene poses significant occupational hazards, it is well-established as a myelotoxin and recognized human carcinogen. Epidemiological and mechanistic studies consistently link occupational and environmental benzene exposure to an increased risk of acute myeloid leukemia (AML). This narrative reviews the evidence for causation, the clinical presentation of AML, the pharmacology of benzene, and risk considerations for affected individuals.

Acute Myeloid Leukemia: Clinical Presentation and Diagnosis

AML is a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid progenitor cells in the bone marrow and peripheral blood. Clinical presentation typically includes symptoms of bone marrow failure, such as fatigue, pallor, infection, and bleeding, due to anemia, neutropenia, and thrombocytopenia. Diagnosis is confirmed by bone marrow biopsy showing at least 20% blasts, along with cytogenetic and molecular testing to identify specific genetic abnormalities. The disease can arise de novo or secondary to prior chemotherapy, radiation, or chemical exposures, including benzene.

Benzene Pharmacology and Reported Adverse Effects

Benzene is a volatile organic compound widely used as an industrial solvent and a component of gasoline. It is absorbed primarily through inhalation and, to a lesser extent, dermal contact. Once in the body, benzene is metabolized in the liver to reactive intermediates, such as benzene oxide, hydroquinone, and muconaldehyde, which can cause oxidative stress, DNA damage, and chromosomal aberrations. Chronic exposure to benzene is acknowledged as a myelotoxin, and it is able to augment the risk for the onset of acute myeloid leukemia, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). The carcinogenic ability of benzene has been reported, and chronic exposure can be one of the risk elements for solid cancers and hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279/).

Mechanistic Pathways Linking Benzene to Acute Myeloid Leukemia

The mode of action (MOA) for benzene-induced AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Possible mechanisms of benzene initiation of hematological tumors have been identified, including a genotoxic effect, an action on oxidative stress and inflammation, and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, it is becoming evident that genetic alterations and other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies, suggesting that epigenetic effects, such as altered gene expression, also play a role (https://pubmed.ncbi.nlm.nih.gov/34069279/). Prevention of these early events would lead to prevention of the apical, adverse outcomes, the morbidity and mortality caused by the myelodysplastic syndromes (MDS) and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Causation-Related Considerations for Affected Patients

Previous studies established a causal relationship between occupational benzene exposure and acute myeloid leukemia (AML) (https://pubmed.ncbi.nlm.nih.gov/38727681/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). In a national cohort from Switzerland, occupational exposure to benzene was associated with elevated mortality risks for AML, diffuse large B-cell lymphoma, and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). Additionally, environmental exposure to benzene has been linked to increased risks of childhood cancers. A meta-analysis of 25 studies found that per 1 μg/m³ increase in benzene exposure, there was an elevated risk of acute myeloid leukemia in children (OR: 1.22, 95% CI: 1.02-1.46; 4 studies; I² = 0.0%) (https://pubmed.ncbi.nlm.nih.gov/41485753/).

Timeline Between Exposure and Documented Harm

The latency period between benzene exposure and the development of AML can vary widely, often ranging from several years to decades. The risk is dose-dependent, with higher cumulative exposures associated with shorter latency and greater risk. The key event-informed risk models suggest that hematotoxicity and genetic toxicity in peripheral blood can be observed as early indicators, and prevention of these early events would prevent the subsequent development of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). The incorporation of key event information should modify the risk model, but few modification approaches have been suggested (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Adequacy of Warnings Regarding Benzene and Acute Myeloid Leukemia

Given the established causal relationship between benzene exposure and AML, adequate warnings are critical for occupational and environmental settings. Regulatory agencies have set permissible exposure limits, but the evidence suggests that even low-level exposures may contribute to risk. The findings from the Swiss National Cohort and other studies underscore the need for continued surveillance and risk communication to protect workers and the public.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between benzene and acute myeloid leukemia?

Benzene is a recognized human carcinogen and myelotoxin. Epidemiological and mechanistic studies consistently link occupational and environmental benzene exposure to an increased risk of acute myeloid leukemia (AML). The causal relationship is well-established, with evidence showing that benzene can cause genetic damage and hematotoxicity leading to AML.

How long does it take for benzene exposure to cause leukemia?

What are the early signs of benzene-induced leukemia?

Early indicators may include hematotoxicity and genetic toxicity in peripheral blood, which can be observed in exposed workers. Prevention of these early events is key to preventing the subsequent development of AML.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.